TABLE 5

PBPK model predictions of the 3D regimen as perpetrators of intestinal and hepatic efflux and hepatic uptake transporters compared with clinical results

Victim Drug (Exposure Ratios with Inhibitors)	Digoxin (P-gp)		Rosuvastatin  (BCRP Plus OATP1B1/1B3)		Pravastatin  (OATP1B1/1B3)
Victim Drug (Exposure Ratios with Inhibitors)	Predicted	Observed^{^a}	Predicted	Observed^{^a}	Predicted	Observed^{^a}
C_max ratio	1.19	1.15	3.42, 4.10^{^b}	7.13	2.0	1.37
AUC ratio	1.20	1.16	2.41, 2.55^{^b}	2.59	2.16	1.82

↵^a Menon et al. (2015).
↵^b Results from sensitivity analysis simulations on paritaprevir and ritonavir in vitro IC₅₀ values against intestinal BCRP.